Dark

Check out our API

ACCD
Accolade, Inc. Common Stock
stock NASDAQ

Inactive

Apr 7, 2025

7.02USD-0.142%(-0.01)4,585,688

Pre-market

0.00USD-100.000%(-7.03)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 11, 2022

04:02PM EST Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in 24th Annual Needham Growth Conference, including a presentation on Friday, January 14, 2022 at 12:30 p.m. E.T. A webcast and related presentation materials will be available at ir.accolade.com. GlobeNewswire Inc

02:51PM EST Mid-Afternoon Market Update: Dow Rises 150 Points; Accolade Shares Spike Higher Benzinga

12:14PM EST Mid-Day Market Update: Crude Oil Rises 3.5%; Pacific Biosciences of California Shares Fall Benzinga

10:19AM EST Shares of Accolade, Inc. (ACCD) are jumping over 25% on Tuesday morning after the company reported a surprise profit for the third quarter and lifted its revenue outlook for the full year. RTTNews

10:18AM EST Looking Into Accolade's Return On Invested Capital Benzinga

10:07AM EST Mid-Morning Market Update: Markets Down; Albertsons Posts Upbeat Earnings Benzinga

07:58AM EST Morgan Stanley Maintains Overweight on Accolade, Lowers Price Target to $30 Benzinga

07:32AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

05:45AM EST Needham Maintains Buy on Accolade, Lowers Price Target to $33 Benzinga

Jan 10, 2022

04:26PM EST Recap: Accolade Q3 Earnings Benzinga

04:11PM EST Accolade Sees Q4 Sales $90M-$93M vs $97.71M Est., Raises FY22 Sales Guidance From $303M-$307M To $306M-$309M vs $306.34M Est. Benzinga

04:09PM EST Accolade Q3 EPS $0.31, Sales $83.45M Beat $75.89M Est. Benzinga

04:05PM EST -- Fiscal third quarter 2022 revenue of $83.5 million, a 117% increase compared to fiscal third quarter 2021 revenue of $38.4 million -- Company introduces preliminary guidance for fiscal year 2023, expecting25% growth in revenue and areduction inAdjusted EBITDA loss -- Initial Accolade One and Accolade Care customerslaunched on January 1, 2022 GlobeNewswire Inc

03:55AM EST Earnings Scheduled For January 10, 2022 Benzinga

Jan 7, 2022

01:06PM EST Earnings Preview: Accolade Benzinga

Dec 17, 2021

08:45AM EST Morgan Stanley Maintains Overweight on Accolade, Lowers Price Target to $31 Benzinga

Dec 16, 2021

08:00AM EST Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives,today announced that it will release fiscal third quarter 2022 financial results on Monday, January 10, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. GlobeNewswire Inc

Dec 2, 2021

11:22AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2021 Benzinga

05:06AM EST Jefferies Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $33 Benzinga

Nov 29, 2021

04:05PM EST Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 400 employers and millions of members, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A presentation is available for registered attendees via the Piper Sandler conference site until December 2, 2021 or can also be accessed at ir.accolade.com. GlobeNewswire Inc

Nov 17, 2021

09:02AM EST Accolade expands world-class executive leadership team with marketing and PR Newswire

Oct 14, 2021

09:04AM EDT Accolade to Showcase Personalized Healthcare for Employers and Health Plans at PR Newswire

Oct 12, 2021

09:05AM EDT Accolade Brings WellRight's Corporate Wellness Programs into its partner PR Newswire

Oct 11, 2021

01:17PM EDT Analyst Ratings For Accolade Benzinga

08:09AM EDT Morgan Stanley Maintains Overweight on Accolade, Lowers Price Target to $56 Benzinga

Oct 8, 2021

12:11PM EDT Expert Ratings For Accolade Benzinga

10:09AM EDT UPDATE: Needham On Accolade Price Target Cut: Firm Warns On 'Recent Broad-Based Multiple Compression Across Digital Health Space'; Highlights Solid Q2 Results Given 32% Proforma Y/Y Growth & Expects Sustainable 30% Growth & Margin Expansion Going Foward Benzinga

09:11AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:13AM EDT Credit Suisse Maintains Outperform on Accolade, Lowers Price Target to $62 Benzinga

05:58AM EDT Needham Maintains Buy on Accolade, Lowers Price Target to $56 Benzinga

04:40AM EDT SVB Leerink Maintains Outperform on Accolade, Lowers Price Target to $52 Benzinga

Oct 7, 2021

04:09PM EDT Accolade Sees Q3 2021 Revs $74.5M-$76.5M Vs $72.72M Est. Benzinga

04:06PM EDT Accolade Q2 EPS $(0.97) Misses $(0.56) Estimate, Sales $73.30M Beat $70.46M Estimate Benzinga

04:05PM EDT Accolade Announces Results for Fiscal Second Quarter 2022 GlobeNewswire Inc

11:17AM EDT How Bad Are Accolade's Earnings? | Return On Invested Capital Benzinga

04:00AM EDT Earnings Scheduled For October 7, 2021 Benzinga

Oct 4, 2021

08:31AM EDT Primary Health Care, Dental Coverage and Investing Platform Connectivity for Hospitality Sector Employees PR Newswire

Sep 30, 2021

11:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 Benzinga

06:09AM EDT Berenberg Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $61 Benzinga

Sep 21, 2021

12:01PM EDT Accolade introduces new healthcare category: Personalized Healthcare PR Newswire

Sep 20, 2021

02:24PM EDT Accolade Invites Media, Investors and General Public to Opening of Evolve21 PR Newswire

10:50AM EDT Accolade Option Alert: Jan 21 $55 Calls Sweep (3) near the Ask: 313 @ $1.75 vs 1333 OI; Earnings 10/7 After Close Ref=$43.77 Benzinga

Sep 17, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021 Benzinga

07:39AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:29AM EDT Baird Upgrades Accolade to Outperform, Lowers Price Target to $54 Benzinga

Sep 16, 2021

08:00AM EDT Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2022 financial results on Thursday, October 7, 2021, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. GlobeNewswire Inc

Sep 7, 2021

04:15PM EDT Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives,will participate in the following upcoming investor conferences: GlobeNewswire Inc

Aug 10, 2021

08:00AM EDT Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the 41st Annual Canaccord Genuity Growth Conference, including a presentation on Thursday, August 12, 2021 at 11:00 a.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com. GlobeNewswire Inc

Jul 29, 2021

02:25PM EDT Looking into Accolade's Return on Capital Employed Benzinga

Jul 22, 2021

10:59AM EDT Return on Capital Employed Overview: Accolade Benzinga

Jul 19, 2021

10:16AM EDT Accolade Option Alert: Oct 15 $65 Calls at the Ask: 500 @ $0.55 vs 1976 OI; Ref=$45.59 Benzinga

Jul 14, 2021

11:01AM EDT Accolade Insights: Return On Capital Employed Benzinga

Jul 9, 2021

02:48PM EDT Analyst Ratings For Accolade Benzinga

10:12AM EDT UPDATE: SVB Leerink On Accolade: Firm Anticipates Continued Execution Across Core Co. Segments; Highlights McKesson Contracting With Co, Humana Employee Expansion Served By Co, And Pepsi Cola Upgrading Total Health And Benefits Solution Benzinga

10:12AM EDT SVB Leerink Maintains Outperform Rating On Accolade With $58 Price Target Benzinga

05:35AM EDT Needham Maintains Buy on Accolade, Raises Price Target to $68 Benzinga

Jul 8, 2021

04:08PM EDT Accolade Sees Q2 Sales $69M-$71M Vs. $62.01M Est.; Raises FY22 Sales Guidance From $260M-$265M To $300M-$305M Vs. $277.86M Est. Benzinga

04:06PM EDT Accolade Q1 EPS $(0.84) Misses $(0.37) Estimate, Sales $59.50M Beat $55.66M Estimate Benzinga

04:05PM EDT Accolade Announces Results for Fiscal First Quarter 2022 GlobeNewswire Inc

04:19AM EDT Earnings Scheduled For July 8, 2021 Benzinga

Jul 7, 2021

08:51AM EDT Credit Suisse Maintains Outperform on Accolade, Raises Price Target to $70 Benzinga

Jul 2, 2021

06:35AM EDT Morgan Stanley Maintains Overweight on Accolade, Raises Price Target to $68 Benzinga

Jun 17, 2021

08:00AM EDT Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives,today announced that it will release fiscal first quarter 2022 financial results on Thursday, July 8, 2021, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. GlobeNewswire Inc

Jun 9, 2021

04:15PM EDT Accolade Completes Acquisition of PlushCare GlobeNewswire Inc

Jun 3, 2021

05:01PM EDT Betsy Nabel and Jeff Brodsky join Accolade Board of Directors PR Newswire

Jun 1, 2021

06:00AM EDT Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives,will participate in the following upcoming investor conferences: GlobeNewswire Inc

May 28, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021 Benzinga

06:31AM EDT Baird Initiates Coverage On Accolade with Neutral Rating, Announces Price Target of $54 Benzinga

May 18, 2021

12:16PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

May 10, 2021

11:00AM EDT Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives,will participate in the following upcoming investor conferences: GlobeNewswire Inc

May 6, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021 Benzinga

07:25AM EDT SVB Leerink Upgrades Accolade to Outperform Benzinga

May 5, 2021

04:05PM EDT Accolade Q4 Adj. EBITDA $2.7M vs $2M In Same Qtr. Last Year, Sales $59.20M Beat $56.57M Estimate Benzinga

04:04PM EDT Accolade Announces Results for Fiscal Fourth Quarter and Full Year GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

Apr 23, 2021

08:01AM EDT Health benefits platform Accolade, Inc. (ACCD) today announced its decision to acquire PlushCare, virtual primary care and mental health treatment provider, in a cash-and-stock deal valued up to $450 million. RTTNews

07:07AM EDT Accolade Signs Definitive Agreement To Acquire PlushCare For Purchase Price Of Up To $450 Mln RTTNews

07:02AM EDT Accolade to Acquire PlushCare; No Terms Disclosed Benzinga

07:00AM EDT Accolade to Acquire PlushCare GlobeNewswire Inc

Apr 19, 2021

08:00AM EDT Accolade to Announce Fiscal Fourth Quarter and Full Year 2021 GlobeNewswire Inc

Apr 15, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021 Benzinga

05:51AM EDT Needham Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $59 Benzinga

Apr 6, 2021

08:44AM EDT Morgan Stanley Maintains Overweight on Accolade, Raises Price Target to $60 Benzinga

Mar 30, 2021

12:04AM EDT Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday Benzinga

Mar 25, 2021

04:29AM EDT Accolade Announces Pricing of $250 Million Convertible Senior GlobeNewswire Inc

Mar 23, 2021

04:05PM EDT Accolade Announces Q4 Preliminary Guidance Of $56.9M-$57.9M Vs $52.59M Estimates; FY21 Sales $168M-$169M Vs $164.1M Estimates Benzinga

04:03PM EDT Accolade Announces Preliminary Results for Fourth Quarter and Full GlobeNewswire Inc

04:02PM EDT Accolade Announces Private Offering of $250 Million Convertible Notes GlobeNewswire Inc

Mar 15, 2021

04:44PM EDT Accolade Announces Offering Of 2.495M Shares Of Common Stock Benzinga

Mar 4, 2021

08:00AM EST Accolade Completes Acquisition of 2nd.MD GlobeNewswire Inc

Mar 2, 2021

06:54PM EST ARK Invest's Cathie Wood To Appear On Benzinga's 'The Raz Report' Wednesday, Mar. 3, 2021 At 2 p.m. EST; Register Early For A Chance To Win To Ask Cathie A Question Live On Air Benzinga

Feb 16, 2021

09:23AM EST Piper Sandler Maintains Overweight on Accolade, Raises Price Target to $60 Benzinga

08:00AM EST Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits,will participate in the following upcoming investor conferences: GlobeNewswire Inc

Feb 4, 2021

09:03AM EST New Independent Study Finds Accolade Significantly Bends the Healthcare Cost PR Newswire

Jan 28, 2021

07:28PM EST CORRECTION: Cathie Wood's ARK Invests' Stock Purchases For Thursday, Jan. 28, 2021: RPTX, ACCD, CDXS, IONS, NVS, FATE, TSLA, EXPC, TER, SKLZ Benzinga

Jan 27, 2021

09:10AM EST Accolade Adds Cindy Kent To Board RTTNews

09:04AM EST Accolade Welcomes Cindy R. Kent to its Board of Directors PR Newswire

Jan 15, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021 Benzinga

09:54AM EST Stock Alert: Accolade Gains 12% On Plan To By Telehealth RTTNews

06:36AM EST Credit Suisse Upgrades Accolade to Outperform, Raises Price Target to $60 Benzinga

05:40AM EST SVB Leerink Maintains Market Perform on Accolade, Raises Price Target to $56 Benzinga

Jan 14, 2021

04:50PM EST Accolade Press Release Confirms Will Buy 2nd.MD For Up To $460M In Cash, Stock, Revenue Milestones Benzinga

04:50PM EST The addition of 2nd.MDs Expert Medical Opinion services to Accolades portfolio of high-touch, technology-enabled health and benefits solutions expands Accolades clinical capabilities and creates the markets most comprehensive, integrated healthcare navigation experience. GlobeNewswire Inc

Jan 11, 2021

08:00AM EST Accolade to Participate in 39th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Jan 8, 2021

09:17AM EST Credit Suisse Maintains Neutral on Accolade, Raises Price Target to $45 Benzinga

06:46AM EST SVB Leerink Maintains Market Perform on Accolade, Raises Price Target to $53 Benzinga

Jan 7, 2021

04:06PM EST Accolade Q3 EPS $(0.32) Beats $(0.35) Estimate, Sales $38.40M Beat $36.19M Estimate Benzinga

04:05PM EST -- Fiscalthirdquarter 2021 revenue of $38.4million, a30% increase compared to fiscalthirdquarter 2020 revenue of $29.7million, driven primarily by strength in new customer additions across market segments and offerings GlobeNewswire Inc

12:10PM EST Benzinga's Top Upgrades, Downgrades For January 7, 2021 Benzinga

06:08AM EST BTIG Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $55 Benzinga

04:10AM EST Earnings Scheduled For January 7, 2021 Benzinga

Dec 23, 2020

08:00AM EST Accolade to Announce Fiscal Third Quarter 2021 Financial Results GlobeNewswire Inc

Dec 17, 2020

05:00AM EST Accolade to Participate in William Blair Healthcare 2021 Focus GlobeNewswire Inc

Dec 8, 2020

09:36AM EST Benzinga's Top Upgrades, Downgrades For December 8, 2020 Benzinga

07:16AM EST Canaccord Genuity Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $59 Benzinga

Nov 20, 2020

08:00AM EST Accolade to Participate in the Piper Sandler 32nd Annual Virtual GlobeNewswire Inc

Nov 17, 2020

09:55AM EST Benzinga's Top Upgrades, Downgrades For November 17, 2020 Benzinga

05:58AM EST Stifel Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $48 Benzinga

Oct 28, 2020

08:30AM EDT Accolade to Participate in the 29th Annual Credit Suisse GlobeNewswire Inc

Oct 26, 2020

04:05PM EDT Accolade Announces Closing of Public Offering and Full Exercise of GlobeNewswire Inc

Oct 22, 2020

12:08AM EDT Accolade Reports Pricing Of Public Offering Of 5 Mln Shares At $38.50 Per Share RTTNews

Oct 19, 2020

04:29PM EDT Accolade Announces Proposed 4.5M Share Common Stock Offering Benzinga

04:28PM EDT Accolade Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Oct 16, 2020

12:28PM EDT Accolade shares are trading higher after Morgan Stanley maintained its Overweight rating on the stock and raised its price target from $37 to $48 per share. UPDATE: Shares have since reversed, now lower. Benzinga

08:12AM EDT Morgan Stanley Maintains Overweight on Accolade, Raises Price Target to $48 Benzinga

Oct 15, 2020

10:18AM EDT B of A Securities Maintains Buy on Accolade, Raises Price Target to $51 Benzinga

07:12AM EDT SVB Leerink Maintains Market Perform on Accolade, Raises Price Target to $44 Benzinga

Oct 14, 2020

04:13PM EDT Accolade Q2 Loss/share $0.47 Vs. Loss $2.82 Year Ago RTTNews

04:03PM EDT Accolade Q2 EPS $(0.47) Misses $(0.40) Estimate, Sales $36.80M Beat $34.62M Estimate Benzinga

04:03PM EDT -- Fiscal second quarter 2021 revenue of $36.8 million, a 24% increase compared to fiscal second quarter 2020 revenue of $29.7 million, driven primarily by strength in new customer adds across segments and offerings -- Continued bookings momentum driving strength in new customer adds across segments and offerings GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 14, 2020 Benzinga

Oct 8, 2020

11:33AM EDT B of A Securities Maintains Buy on Accolade, Raises Price Target to $45 Benzinga

Oct 1, 2020

09:03AM EDT Accolade partners with the Global Appropriateness Measures group to bring PR Newswire

Sep 24, 2020

06:00AM EDT Accolade to Announce Fiscal Second Quarter 2021 Financial Results GlobeNewswire Inc

Sep 22, 2020

06:53AM EDT DA Davidson Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $45 Benzinga

Sep 17, 2020

09:02AM EDT Accolade Introduces First Employer Health and Benefits Solution that Integrates PR Newswire

Sep 1, 2020

08:30AM EDT Accolade to Participate in the Morgan Stanley 18th Annual GlobeNewswire Inc

Aug 14, 2020

11:19AM EDT Credit Suisse Maintains Neutral on Accolade, Raises Price Target to $40 Benzinga

05:18AM EDT SVB Leerink Maintains Market Perform on Accolade, Raises Price Target to $40 Benzinga

Aug 13, 2020

04:09PM EDT Accolade Sees Q2 Sales $34.5M-$35.5M vs $34.64M Est., Sees FY21 Sales $158.0M-$161.0M vs $159.07M Est. Benzinga

04:07PM EDT Accolade Q2 EPS $(1.86) May Not Compare To $(0.40) Estimate, Sales $35.90M Beat $34.51M Estimate Benzinga

04:03PM EDT -- Fiscal first quarter 2021 revenue of $35.9 million, a 25% increase compared to fiscal first quarter 2020 revenue of $28.8 million, driven primarily by strength in new customer adds across segments and offerings GlobeNewswire Inc

04:03AM EDT Earnings Scheduled For August 13, 2020 Benzinga

Jul 27, 2020

10:16AM EDT B of A Securities Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $37 Benzinga

09:33AM EDT Benzinga's Top Upgrades, Downgrades For July 27, 2020 Benzinga

09:00AM EDT Accolade to Announce Fiscal First Quarter 2021 Financial Results GlobeNewswire Inc

07:46AM EDT Credit Suisse Initiates Coverage On Accolade with Neutral Rating, Announces Price Target of $38 Benzinga

06:44AM EDT SVB Leerink Initiates Coverage On Accolade with Market Perform Rating, Announces Price Target of $34 Benzinga

06:33AM EDT Morgan Stanley Initiates Coverage On Accolade with Overweight Rating, Announces Price Target of $37 Benzinga

06:32AM EDT Goldman Sachs Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $39 Benzinga

05:26AM EDT Piper Sandler Initiates Coverage On Accolade with Overweight Rating, Announces Price Target of $45 Benzinga

Jul 16, 2020

04:56PM EDT J. Michael Cline Reports 20.8% Active Stake In Accolade Benzinga

Share